MNKD Quote, Financials, Valuation and Earnings

NovaBay Pharmaceuticals has a net margin of 16.79% compared to MannKind's net margin of -49.65%. MannKind's return on equity of -- beat NovaBay Pharmaceuticals's return on equity of -461.38%.

MannKind has a consensus price target of $10.29, signalling upside risk potential of 134.83%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 46.55%. Given that MannKind has higher upside potential than NovaBay Pharmaceuticals, analysts believe MannKind is more attractive than NovaBay Pharmaceuticals.

MannKind has a beta of 1.018, which suggesting that the stock is 1.757% more volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.427, suggesting its less volatile than the S&P 500 by 57.305%.

MannKind has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. MannKind pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

MannKind quarterly revenues are $78.4M, which are larger than NovaBay Pharmaceuticals quarterly revenues of $2.4M. MannKind's net income of $13.2M is higher than NovaBay Pharmaceuticals's net income of $7.7M. Notably, MannKind's price-to-earnings ratio is 43.80x while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for MannKind is 4.30x versus 0.16x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Sarepta Therapeutics has a net margin of 16.79% compared to MannKind's net margin of -60.08%. MannKind's return on equity of -- beat Sarepta Therapeutics's return on equity of -20.94%.

MannKind has a consensus price target of $10.29, signalling upside risk potential of 134.83%. On the other hand Sarepta Therapeutics has an analysts' consensus of $89.96 which suggests that it could grow by 109.16%. Given that MannKind has higher upside potential than Sarepta Therapeutics, analysts believe MannKind is more attractive than Sarepta Therapeutics.

MannKind has a beta of 1.018, which suggesting that the stock is 1.757% more volatile than S&P 500. In comparison Sarepta Therapeutics has a beta of 0.609, suggesting its less volatile than the S&P 500 by 39.15%.

MannKind has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sarepta Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. MannKind pays -- of its earnings as a dividend. Sarepta Therapeutics pays out -- of its earnings as a dividend.

MannKind quarterly revenues are $78.4M, which are smaller than Sarepta Therapeutics quarterly revenues of $744.9M. MannKind's net income of $13.2M is higher than Sarepta Therapeutics's net income of -$447.5M. Notably, MannKind's price-to-earnings ratio is 43.80x while Sarepta Therapeutics's PE ratio is 20.50x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for MannKind is 4.30x versus 2.14x for Sarepta Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Theriva Biologics has a net margin of 16.79% compared to MannKind's net margin of --. MannKind's return on equity of -- beat Theriva Biologics's return on equity of --.

MannKind has a consensus price target of $10.29, signalling upside risk potential of 134.83%. On the other hand Theriva Biologics has an analysts' consensus of $7.00 which suggests that it could grow by 1389.36%. Given that Theriva Biologics has higher upside potential than MannKind, analysts believe Theriva Biologics is more attractive than MannKind.

MannKind has a beta of 1.018, which suggesting that the stock is 1.757% more volatile than S&P 500. In comparison Theriva Biologics has a beta of 0.848, suggesting its less volatile than the S&P 500 by 15.165%.

MannKind has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. MannKind pays -- of its earnings as a dividend. Theriva Biologics pays out -- of its earnings as a dividend.

MannKind quarterly revenues are $78.4M, which are larger than Theriva Biologics quarterly revenues of --. MannKind's net income of $13.2M is higher than Theriva Biologics's net income of -$4.3M. Notably, MannKind's price-to-earnings ratio is 43.80x while Theriva Biologics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for MannKind is 4.30x versus 0.33x for Theriva Biologics. Usually stocks with elevated PS ratios are considered overvalued.

Vertex Pharmaceuticals has a net margin of 16.79% compared to MannKind's net margin of 23.33%. MannKind's return on equity of -- beat Vertex Pharmaceuticals's return on equity of -6.04%.

MannKind has a consensus price target of $10.29, signalling upside risk potential of 134.83%. On the other hand Vertex Pharmaceuticals has an analysts' consensus of $500.12 which suggests that it could grow by 11.02%. Given that MannKind has higher upside potential than Vertex Pharmaceuticals, analysts believe MannKind is more attractive than Vertex Pharmaceuticals.

MannKind has a beta of 1.018, which suggesting that the stock is 1.757% more volatile than S&P 500. In comparison Vertex Pharmaceuticals has a beta of 0.415, suggesting its less volatile than the S&P 500 by 58.544%.

MannKind has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vertex Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. MannKind pays -- of its earnings as a dividend. Vertex Pharmaceuticals pays out -- of its earnings as a dividend.

MannKind quarterly revenues are $78.4M, which are smaller than Vertex Pharmaceuticals quarterly revenues of $2.8B. MannKind's net income of $13.2M is lower than Vertex Pharmaceuticals's net income of $646.3M. Notably, MannKind's price-to-earnings ratio is 43.80x while Vertex Pharmaceuticals's PE ratio is 26.10x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for MannKind is 4.30x versus 10.51x for Vertex Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.